Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial

NEXT STORY
CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
PREV STORY
In vitro Diagnostics Market is Forecast to Rise at 4.5% CAGR and Reach USD 87.11 Billion by 2026; Launch of Altostar Molecular Diagnostics Workflow by Altona Diagnostics Gmbh Will Support Growth, says Fortune Business Insights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) ...

author_avatar
NASDAQ Market News

OSE Immunotherapeutics is Pleased to Announce the Continuation of its Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis after the Interim Futility Analysis

author_avatar
NASDAQ Market News

Adaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference

author_avatar
NASDAQ Market News